This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignees: University of California, Frontier Medicines Corporation, Novartis Ag. Active years: 2023-2024.
Company Filing History:
2 out of 15,988 
1 out of 2 
1 out of 3,974 
Years Active: 2023-2024
Title: The Innovations of Carl C. Ward
Introduction
Carl C. Ward is a notable inventor based in Berkeley, CA (US), recognized for his contributions to the field of targeted protein degradation and autophagy. With a total of 2 patents, his work has significant implications in pharmaceutical development and therapeutic strategies.
Latest Patents
Ward's latest patents include "Covalent targeting of E3 ligases," which discloses compositions and methods for targeting E3 ligases. This patent describes a targeted protein degrader that includes a targeted protein binder and an E3 Ubiquitin ligase binder, specifically human RNF4 or human RNF114. Additionally, he has developed methods and compounds for "targeted autophagy," which provide innovative approaches to enhance autophagic processes in cells.
Career Highlights
Throughout his career, Carl C. Ward has worked with prestigious organizations such as the University of California and Novartis AG. His experience in these institutions has allowed him to advance his research and contribute to significant scientific advancements.
Collaborations
Ward has collaborated with esteemed colleagues, including Daniel K. Nomura and Jessica Spradlin, further enriching his research endeavors and expanding the impact of his work.
Conclusion
Carl C. Ward's innovative patents and collaborations highlight his significant role in advancing the fields of protein degradation and autophagy. His contributions continue to influence pharmaceutical research and development.